Axcynsis Therapeutics Pte Ltd. has described antibody-drug conjugates comprising an antibody or antigen-binding fragment targeting alkaline phosphatase placental type (ALPP) and/or alkaline phosphatase, germ cell type (ALPPL2) covalently linked to a cytotoxic agent through a linker reported to be useful for the treatment of cancer.
The antibody-drug conjugate (ADC) juggernaut powers on, with Japan’s Taiho Pharmaceutical Co. set to acquire Araris Biotech AG for up to $1.14 billion. Of that, $400 million will be up front, with the remainder tied to milestones with a maximum value of $740 million, around the progress of three ADCs for treating solid and hematological cancers.
Researchers at Concept to Medicine Biotech Co. Ltd., Lepu Biopharma Co. Ltd. and Shanghai Miracogen Inc. have described antibody-drug conjugates consisting of trophoblast glycoprotein (TPBG, 5T4)-targeting antibodies covalently linked to cytotoxic drugs through linkers reported to be useful for the treatment of cancer.
Alteogen Inc. signed its first billion-dollar partnership this year for ALT-B4 technology through two separate contracts with Astrazeneca plc’s U.K.- and U.S.-based Medimmune subsidiaries worth up to $1.35 billion combined.
The antibody-drug conjugate (ADC) juggernaut powers on, with Japan’s Taiho Pharmaceutical Co. set to acquire Araris Biotech AG for up to $1.14 billion. Of that, $400 million will be up front, with the remainder tied to milestones with a maximum value of $740 million, around the progress of three ADCs for treating solid and hematological cancers.
Alteogen Inc. signed its first billion-dollar partnership this year for ALT-B4 technology through two separate contracts with Astrazeneca plc’s U.K.- and U.S.-based Medimmune subsidiaries worth up to $1.35 billion combined.
Sotio Biotech AS is exercising an option under a license and option agreement to obtain a license to Synaffix BV’s technology to develop two bispecific antibody-drug conjugate (ADC) programs for solid tumors.
Sutro Biopharma Inc. has announced plans to prioritize its three wholly owned preclinical programs in its next-generation antibody-drug conjugate (ADC) pipeline, while deprioritizing additional investment into development of luveltamab tazevibulin across all indications.
Inatherys SAS recently presented preclinical data for INA-03, an anti-transferrin receptor (TfR1/CD71) antibody-drug conjugate (ADC), being developed for the treatment of triple-negative breast cancer (TNBC). INA-03 was constructed by conjugating an antimitotic payload (MMAE) to a humanized IgG4 anti-human CD71 antibody using a novel valine-citrulline linker.
RSS
